Clinical and experimental study on treatment of acute cerebral infarction by zhongfeng no. II oral liquid.
- Author:
Heng-zhao ZHU
1
;
An ZHENG
;
Dong LI
Author Information
- Publication Type:Clinical Trial
- MeSH: Administration, Oral; Aged; Animals; Cerebral Infarction; blood; drug therapy; Drugs, Chinese Herbal; therapeutic use; Female; Gerbillinae; Glutamic Acid; metabolism; Humans; Male; Middle Aged; Neuroprotective Agents; therapeutic use; Phytotherapy; Random Allocation; Superoxide Dismutase; metabolism
- From:Chinese Journal of Integrated Traditional and Western Medicine 2002;22(1):37-39
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the effect and mechanism of Zhongfeng No. II Oral Liquid (ZF II) in treating acute cerebral infarction (CI).
METHODSRandomly controlled clinical study was conducted in 160 patients with CI, they were treated with ZF II plus western medicine (treated group) and western medicine alone (control group) respectively. The animal model of CI was made by unilaterally common carotid artery ligation in 45 Mongolian gerbil, and they were divided into the model group, the normal saline group and ZF II group.
RESULTSZF II could improve the TCM Syndrome, neuro-function and cerebral blood circulation in CI patients. Experimental study showed that ZF II could significantly inhibit the release of glutamic acid in 6 hrs (P < 0.05), maintain the level of superoxide dismutase (SOD) and glutathione, and scavenge the free radicals effectively.
CONCLUSIONZF II could improve the function of brain tissue, and is worth developing and applying in treating CI.
